NASDAQ:ARWR - Arrowhead Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$10.05 +0.28 (+2.87 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close$10.05
Today's Range$9.78 - $10.18
52-Week Range$1.42 - $10.38
Volume1.44 million shs
Average Volume1.63 million shs
Market Capitalization$855.63 million
P/E Ratio-21.38
Dividend YieldN/A
Beta2.41

About Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Arrowhead Pharmaceuticals logoArrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pre-clinical stage medicines include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; ARO-APOC3 and ARO-ANG3 to treat hypertriglyceridemia; ARO-Lung1 for the treatment of an undisclosed pulmonary target; ARO-HIF2 to treat renal cell carcinoma; ARO-F12 for hereditary angioedema and thromboembolic disorders; and ARO-AMG1 for the treatment of an undisclosed genetically validated cardiovascular target. Arrowhead Pharmaceuticals, Inc. has collaboration and license agreement with Amgen, Inc. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.

Receive ARWR News and Ratings via Email

Sign-up to receive the latest news and ratings for ARWR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ARWR
CUSIPN/A
Phone626-304-3400

Debt

Debt-to-Equity Ratio0.02
Current Ratio10.16
Quick Ratio10.16

Price-To-Earnings

Trailing P/E Ratio-21.38
Forward P/E Ratio-13.58
P/E GrowthN/A

Sales & Book Value

Annual Sales$31.41 million
Price / Sales28.02
Cash FlowN/A
Price / CashN/A
Book Value$1.30 per share
Price / Book7.73

Profitability

EPS (Most Recent Fiscal Year)($0.47)
Net Income$-34,380,000.00
Net Margins-199.55%
Return on Equity-50.05%
Return on Assets-40.83%

Miscellaneous

Employees93
Outstanding Shares87,580,000

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Frequently Asked Questions

What is Arrowhead Pharmaceuticals' stock symbol?

Arrowhead Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARWR."

How were Arrowhead Pharmaceuticals' earnings last quarter?

Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) released its quarterly earnings data on Tuesday, May, 8th. The biotechnology company reported ($0.18) earnings per share for the quarter, beating analysts' consensus estimates of ($0.19) by $0.01. The biotechnology company earned $0.65 million during the quarter, compared to analyst estimates of $4.04 million. Arrowhead Pharmaceuticals had a negative net margin of 199.55% and a negative return on equity of 50.05%. View Arrowhead Pharmaceuticals' Earnings History.

When is Arrowhead Pharmaceuticals' next earnings date?

Arrowhead Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, August, 1st 2018. View Earnings Estimates for Arrowhead Pharmaceuticals.

What price target have analysts set for ARWR?

6 brokers have issued twelve-month target prices for Arrowhead Pharmaceuticals' shares. Their predictions range from $4.00 to $13.00. On average, they anticipate Arrowhead Pharmaceuticals' share price to reach $9.00 in the next year. View Analyst Ratings for Arrowhead Pharmaceuticals.

What are Wall Street analysts saying about Arrowhead Pharmaceuticals stock?

Here are some recent quotes from research analysts about Arrowhead Pharmaceuticals stock:
  • 1. Chardan Capital analysts commented, "We believe that Arrowhead is positioned to achieve a number of significant milestones in 2018. The Company spent most of 2017 quietly regrouping following its announcement in November 2016 that it was discontinuing all of its clinical RNAi programs (ARC-520, ARC-521, and ARC-AAT), which use its dynamic polyconjugate (DPC) delivery technology. The decision to discontinue development of these programs was based on the substantial delays that would have occurred in order to further explore the cause of deaths in a non-clinical toxicology study in non-human primates. Arrowhead subsequently reduced its workforce by approximately 30%. In September 2017, the Company unveiled its new proprietary delivery technology they call Targeted RNAi Molecule (TRiM), along with a portfolio of newly named candidates. Arrowhead’s TRiM delivery technology leverages advances in RNA chemistry and targeting, to deliver a payload with increased potency." (2/19/2018)
  • 2. Cantor Fitzgerald analysts commented, "Arrowhead reiterated its recently disclosed timeline for returning to clinical development with at least two indications (AAT and HBV) in 1H18." (9/25/2017)

Who are some of Arrowhead Pharmaceuticals' key competitors?

Who are Arrowhead Pharmaceuticals' key executives?

Arrowhead Pharmaceuticals' management team includes the folowing people:
  • Dr. Christopher R. Anzalone, CEO, Pres & Director (Age 49)
  • Mr. Kenneth A. Myszkowski, Chief Financial Officer (Age 52)
  • Dr. Bruce D. Given, Chief Operating Officer (Age 64)
  • Mr. Patrick O'Brien, Gen. Counsel (Age 54)
  • Dr. Mark M. Davis Ph.D., Founder and Founder & Director of Insert Therapeutics Inc & Calando

Has Arrowhead Pharmaceuticals been receiving favorable news coverage?

News stories about ARWR stock have been trending somewhat negative recently, Accern Sentiment reports. Accern identifies positive and negative news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Arrowhead Pharmaceuticals earned a daily sentiment score of -0.02 on Accern's scale. They also gave media headlines about the biotechnology company an impact score of 45.85 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

Who are Arrowhead Pharmaceuticals' major shareholders?

Arrowhead Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include OppenheimerFunds Inc. (8.91%), RTW INVESTMENTS, LP (5.02%), BlackRock Inc. (3.92%), Acuta Capital Partners LLC (2.01%), Nexthera Capital LP (1.27%) and Millennium Management LLC (0.93%). Company insiders that own Arrowhead Pharmaceuticals stock include Bruce D Given, Christopher Richard Anzalone, Douglas B Given and Kenneth Allen Myszkowski. View Institutional Ownership Trends for Arrowhead Pharmaceuticals.

Which institutional investors are selling Arrowhead Pharmaceuticals stock?

ARWR stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, A.R.T. Advisors LLC, Alpine Global Management LLC and Barclays PLC. Company insiders that have sold Arrowhead Pharmaceuticals company stock in the last year include Bruce D Given, Christopher Richard Anzalone, Douglas B Given and Kenneth Allen Myszkowski. View Insider Buying and Selling for Arrowhead Pharmaceuticals.

Which institutional investors are buying Arrowhead Pharmaceuticals stock?

ARWR stock was bought by a variety of institutional investors in the last quarter, including Acuta Capital Partners LLC, OppenheimerFunds Inc., Nexthera Capital LP, BlackRock Inc., Iguana Healthcare Management LLC, UBS Group AG, Tibra Equities Europe Ltd and GSA Capital Partners LLP. View Insider Buying and Selling for Arrowhead Pharmaceuticals.

How do I buy shares of Arrowhead Pharmaceuticals?

Shares of ARWR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Arrowhead Pharmaceuticals' stock price today?

One share of ARWR stock can currently be purchased for approximately $10.05.

How big of a company is Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals has a market capitalization of $855.63 million and generates $31.41 million in revenue each year. The biotechnology company earns $-34,380,000.00 in net income (profit) each year or ($0.47) on an earnings per share basis. Arrowhead Pharmaceuticals employs 93 workers across the globe.

How can I contact Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals' mailing address is 225 SOUTH LAKE AVENUE SUITE 1050, PASADENA CA, 91101. The biotechnology company can be reached via phone at 626-304-3400 or via email at [email protected]


MarketBeat Community Rating for Arrowhead Pharmaceuticals (ARWR)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  222 (Vote Outperform)
Underperform Votes:  158 (Vote Underperform)
Total Votes:  380
MarketBeat's community ratings are surveys of what our community members think about Arrowhead Pharmaceuticals and other stocks. Vote "Outperform" if you believe ARWR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARWR will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
6 Wall Street analysts have issued ratings and price targets for Arrowhead Pharmaceuticals in the last 12 months. Their average twelve-month price target is $9.00, suggesting that the stock has a possible downside of 10.45%. The high price target for ARWR is $13.00 and the low price target for ARWR is $4.00. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyHold
Consensus Rating Score: 2.832.672.502.40
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $9.00$6.30$4.70$2.70
Price Target Upside: 10.45% downside9.22% downside15.62% downside27.03% downside

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Consensus Price Target History

Price Target History for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/8/2018Piper Jaffray CompaniesBoost Price TargetOverweight$11.00HighView Rating Details
5/8/2018Cantor FitzgeraldUpgradeNeutral ➝ Overweight$13.00HighView Rating Details
3/27/2018Jefferies GroupInitiated CoverageBuy$10.00HighView Rating Details
2/19/2018Chardan CapitalReiterated RatingBuy$7.00LowView Rating Details
2/12/2018B. RileyBoost Price TargetNeutral ➝ Neutral$3.00 ➝ $4.00MediumView Rating Details
9/18/2017William BlairUpgradeMarket Perform ➝ OutperformHighView Rating Details
(Data available from 5/26/2016 forward)

Earnings

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Earnings History and Estimates Chart

Earnings by Quarter for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Earnings Estimates

2018 EPS Consensus Estimate: ($0.65)
2019 EPS Consensus Estimate: ($0.75)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.13)($0.13)($0.13)
Q2 20184($0.20)($0.13)($0.17)
Q3 20185($0.20)($0.12)($0.17)
Q4 20185($0.20)($0.13)($0.18)
Q1 20193($0.22)($0.11)($0.18)
Q2 20193($0.23)($0.11)($0.19)
Q3 20193($0.23)($0.11)($0.19)
Q4 20193($0.24)($0.10)($0.19)

Arrowhead Pharmaceuticals (NASDAQ ARWR) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/1/2018($0.19)N/AView Earnings Details
5/8/2018Q2 2018($0.19)($0.18)$4.04 million$0.65 millionViewN/AView Earnings Details
2/9/2018Q1 2018($0.14)($0.18)$8.71 million$3.51 millionViewListenView Earnings Details
12/12/2017Q4 2017($0.12)($0.14)$7.32 million$8.71 millionViewN/AView Earnings Details
8/3/2017Q3 2017($0.13)($0.07)$5.29 million$9.34 millionViewListenView Earnings Details
5/3/2017Q2 2017($0.1230)($0.08)$4.19 million$8.99 millionViewListenView Earnings Details
2/6/2017Q117($0.20)($0.17)$13.24 million$4.37 millionViewListenView Earnings Details
12/14/2016Q4 2016($0.33)($0.31)$0.04 million$0.03 millionViewN/AView Earnings Details
8/9/2016Q316($0.37)($0.32)$0.05 million$39.58 millionViewN/AView Earnings Details
5/10/2016Q216($0.37)($0.35)$0.26 million$0.04 millionViewListenView Earnings Details
2/9/2016Q1($0.41)($0.32)$0.29 million$0.04 millionViewN/AView Earnings Details
12/14/2015Q415($0.39)($0.42)$0.14 million$0.04 millionViewListenView Earnings Details
8/4/2015Q315($0.38)($0.27)$0.11 million$0.12 millionViewN/AView Earnings Details
5/11/2015Q214($0.35)($0.33)$110.00 million$43.75 millionViewListenView Earnings Details
2/9/2015Q114($0.32)($0.41)$0.24 million$0.17 millionViewN/AView Earnings Details
11/25/2014Q413($0.25)($0.33)$0.04 million$0.04 millionViewN/AView Earnings Details
8/12/2014Q313($0.22)($0.22)$0.04 million$0.04 millionViewN/AView Earnings Details
5/6/2014Q2 2014($0.18)($0.31)$0.05 million$0.04 millionViewN/AView Earnings Details
2/4/2014Q4($0.18)($0.33)$0.05 million$0.04 millionViewN/AView Earnings Details
12/18/2013Q4($0.23)($0.43)ViewListenView Earnings Details
8/7/2013Q3 2013($0.22)($0.23)$0.50 million$0.04 millionViewN/AView Earnings Details
5/9/2013Q2 2013($0.41)$0.04 millionViewN/AView Earnings Details
2/13/2013Q1 2013($0.33)ViewN/AView Earnings Details
12/20/2012Q4 2012($0.43)ViewN/AView Earnings Details
8/13/2012Q3 2012($0.71)ViewN/AView Earnings Details
5/8/2012Q2 2012($0.44)ViewN/AView Earnings Details
2/9/2012Q1 2012($0.25)ViewN/AView Earnings Details
12/20/2011Q4 2011($0.39)ViewN/AView Earnings Details
8/8/2011Q3 2011($0.20)($0.26)ViewN/AView Earnings Details
5/12/2011Q2 2011($0.20)($0.18)ViewN/AView Earnings Details
2/10/2011Q1 2011($0.20)ViewN/AView Earnings Details
12/22/2010Q4 2010($0.30)($0.28)ViewN/AView Earnings Details
8/12/2010Q3 2010($0.50)($0.06)ViewN/AView Earnings Details
5/13/2010Q2 2010($0.40)($0.33)ViewN/AView Earnings Details
2/11/2010Q1 2010($0.30)ViewN/AView Earnings Details
12/22/2009Q4 2009($0.60)ViewN/AView Earnings Details
8/10/2009Q3 2009($0.60)ViewN/AView Earnings Details
5/15/2009Q2 2009($1.20)ViewN/AView Earnings Details
2/9/2009Q1 2009($1.90)ViewN/AView Earnings Details
12/15/2008Q4 2008($2.14)ViewN/AView Earnings Details
8/11/2008Q3 2008($1.90)ViewN/AView Earnings Details
2/11/2008Q1 2008($1.40)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Arrowhead Pharmaceuticals (NASDAQ ARWR) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.60%
Institutional Ownership Percentage: 44.58%
Insider Trading History for Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Institutional Ownership by Quarter for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Arrowhead Pharmaceuticals (NASDAQ ARWR) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/24/2018Douglas B. GivenDirectorSell25,000$6.63$165,750.00View SEC Filing  
3/27/2018Kenneth Allen MyszkowskiCFOSell20,000$8.00$160,000.00330,815View SEC Filing  
3/15/2018Christopher Richard AnzaloneCEOSell300,000$7.43$2,229,000.002,194,789View SEC Filing  
3/13/2018Christopher Richard AnzaloneCEOSell100,000$7.43$743,000.002,194,789View SEC Filing  
3/5/2018Bruce D GivenCOOSell20,000$6.73$134,600.00908,356View SEC Filing  
1/1/2018Bruce D GivenCOOSell20,000$3.69$73,800.00948,356View SEC Filing  
10/14/2016Douglas B. GivenDirectorSell12,000$6.72$80,640.00View SEC Filing  
8/23/2016Kenneth Allen MyszkowskiCFOSell6,900$8.00$55,200.00128,789View SEC Filing  
8/22/2016Kenneth Allen MyszkowskiCFOSell13,100$8.00$104,800.00128,789View SEC Filing  
12/30/2015Kenneth Allen MyszkowskiCFOSell23,347$6.13$143,117.11135,000View SEC Filing  
10/28/2015Mauro FerrariDirectorBuy400$7.62$3,048.00View SEC Filing  
10/9/2015Mauro FerrariDirectorBuy1,900$6.19$11,761.00View SEC Filing  
1/5/2015David L LewisInsiderSell15,000$8.01$120,150.00View SEC Filing  
10/15/2014Christopher Richard AnzaloneCEOBuy16,000$6.32$101,120.00View SEC Filing  
10/1/2014Charles MckenneyDirectorSell2,500$14.70$36,750.00View SEC Filing  
9/30/2014David L LewisInsiderSell15,000$15.02$225,300.00View SEC Filing  
9/26/2014Douglas B GivenDirectorSell2,000$15.24$30,480.00View SEC Filing  
6/9/2014Charles MckenneyDirectorSell22,000$14.32$315,040.00View SEC Filing  
2/12/2014Kenneth Allen MyszkowskiCFOSell16,000$18.77$300,320.00View SEC Filing  
2/7/2014Edward W FrykmanDirectorSell3,148$15.98$50,305.04View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Arrowhead Pharmaceuticals (NASDAQ ARWR) News Headlines

Source:
DateHeadline
Arrowhead Pharmaceuticals to Post FY2018 Earnings of ($0.76) Per Share, Cantor Fitzgerald Forecasts (ARWR)Arrowhead Pharmaceuticals to Post FY2018 Earnings of ($0.76) Per Share, Cantor Fitzgerald Forecasts (ARWR)
www.americanbankingnews.com - May 24 at 8:50 AM
Arrowhead Pharmaceuticals Presents New Preclinical Data on ARO-ENaC for Treatment of Cystic FibrosisArrowhead Pharmaceuticals Presents New Preclinical Data on ARO-ENaC for Treatment of Cystic Fibrosis
www.bizjournals.com - May 21 at 8:46 AM
Arrowhead Pharmaceuticals (ARWR) Receives Consensus Rating of "Buy" from BrokeragesArrowhead Pharmaceuticals (ARWR) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - May 21 at 3:40 AM
Arrowhead Pharmaceuticals (ARWR) Expected to Announce Quarterly Sales of $610,000.00Arrowhead Pharmaceuticals (ARWR) Expected to Announce Quarterly Sales of $610,000.00
www.americanbankingnews.com - May 19 at 1:55 AM
Arrowhead Pharmaceuticals - Here Come The Institutions And What That Could MeanArrowhead Pharmaceuticals - Here Come The Institutions And What That Could Mean
seekingalpha.com - May 18 at 5:17 PM
Zacks: Analysts Expect Arrowhead Pharmaceuticals (ARWR) Will Post Earnings of -$0.19 Per ShareZacks: Analysts Expect Arrowhead Pharmaceuticals (ARWR) Will Post Earnings of -$0.19 Per Share
www.americanbankingnews.com - May 17 at 11:15 PM
Form SC 13G ARROWHEAD PHARMACEUTICAL Filed by: RTW INVESTMENTS, LPForm SC 13G ARROWHEAD PHARMACEUTICAL Filed by: RTW INVESTMENTS, LP
www.streetinsider.com - May 16 at 9:00 AM
Investors Buy Large Volume of Arrowhead Pharmaceuticals Put Options (ARWR)Investors Buy Large Volume of Arrowhead Pharmaceuticals Put Options (ARWR)
www.americanbankingnews.com - May 16 at 6:56 AM
Edited Transcript of ARWR earnings conference call or presentation 8-May-18 8:30pm GMTEdited Transcript of ARWR earnings conference call or presentation 8-May-18 8:30pm GMT
finance.yahoo.com - May 15 at 5:22 PM
Wired News – Arrowhead Pharma Presented Preclinical Data on Expanding Pipeline of RNAi Therapeutics for Cardiometabolic DiseasesWired News – Arrowhead Pharma Presented Preclinical Data on Expanding Pipeline of RNAi Therapeutics for Cardiometabolic Diseases
finance.yahoo.com - May 15 at 8:39 AM
Arrowhead Pharmaceuticals Corp (ARWR) Reports Dosing of 1st Hepatitis B Patient in Multiple Dose Portion of Phase 1/2 Study of ARO-HBVArrowhead Pharmaceuticals Corp (ARWR) Reports Dosing of 1st Hepatitis B Patient in Multiple Dose Portion of Phase 1/2 Study of ARO-HBV
www.streetinsider.com - May 14 at 5:14 PM
Arrowhead Doses First Hepatitis B Patients in Multiple Dose Portion of Phase 1/2 Study of ARO-HBVArrowhead Doses First Hepatitis B Patients in Multiple Dose Portion of Phase 1/2 Study of ARO-HBV
finance.yahoo.com - May 14 at 9:55 AM
Q3 2018 Earnings Forecast for Arrowhead Pharmaceuticals (ARWR) Issued By Jefferies GroupQ3 2018 Earnings Forecast for Arrowhead Pharmaceuticals (ARWR) Issued By Jefferies Group
www.americanbankingnews.com - May 14 at 3:13 AM
BRIEF-Arrowhead Pharmaceuticals Presents Preclinical Data On Expanding Cardiometabolic PipelineBRIEF-Arrowhead Pharmaceuticals Presents Preclinical Data On Expanding Cardiometabolic Pipeline
www.reuters.com - May 13 at 8:57 AM
Arrowhead Pharmaceuticals (ARWR) Upgraded to "Buy" at BidaskClubArrowhead Pharmaceuticals (ARWR) Upgraded to "Buy" at BidaskClub
www.americanbankingnews.com - May 12 at 5:01 PM
Jefferies Group Weighs in on Arrowhead Pharmaceuticals FY2019 Earnings (ARWR)Jefferies Group Weighs in on Arrowhead Pharmaceuticals' FY2019 Earnings (ARWR)
www.americanbankingnews.com - May 11 at 11:42 AM
Q3 2018 EPS Estimates for Arrowhead Pharmaceuticals (ARWR) Boosted by William BlairQ3 2018 EPS Estimates for Arrowhead Pharmaceuticals (ARWR) Boosted by William Blair
www.americanbankingnews.com - May 11 at 10:01 AM
Arrowhead Pharmaceuticals to Post Q3 2018 Earnings of ($0.18) Per Share, B. Riley Forecasts (ARWR)Arrowhead Pharmaceuticals to Post Q3 2018 Earnings of ($0.18) Per Share, B. Riley Forecasts (ARWR)
www.americanbankingnews.com - May 11 at 10:01 AM
Q3 2018 Earnings Forecast for Arrowhead Pharmaceuticals (ARWR) Issued By Piper JaffrayQ3 2018 Earnings Forecast for Arrowhead Pharmaceuticals (ARWR) Issued By Piper Jaffray
www.americanbankingnews.com - May 11 at 10:01 AM
5 Momentum Stocks Moving on Earnings5 Momentum Stocks Moving on Earnings
www.nasdaq.com - May 10 at 5:15 PM
Four momentum stocks to watch amid earnings reportsFour momentum stocks to watch amid earnings reports
finance.yahoo.com - May 10 at 5:15 PM
Arrowhead Pharmaceuticals (ARWR) Releases  Earnings Results, Beats Estimates By $0.01 EPSArrowhead Pharmaceuticals (ARWR) Releases Earnings Results, Beats Estimates By $0.01 EPS
www.americanbankingnews.com - May 9 at 5:26 PM
Form 10-Q ARROWHEAD PHARMACEUTICAL For: Mar 31Form 10-Q ARROWHEAD PHARMACEUTICAL For: Mar 31
www.streetinsider.com - May 9 at 8:37 AM
Recent Analysis Shows Extreme Networks, Lumber Liquidators, Owens-Illinois, Arrowhead Pharmaceuticals, Intrepid ...Recent Analysis Shows Extreme Networks, Lumber Liquidators, Owens-Illinois, Arrowhead Pharmaceuticals, Intrepid ...
globenewswire.com - May 9 at 8:37 AM
BRIEF-Arrowhead Pharmaceuticals Reports Qtrly Loss Per Share $0.18BRIEF-Arrowhead Pharmaceuticals Reports Qtrly Loss Per Share $0.18
www.reuters.com - May 9 at 8:37 AM
Arrowhead Pharmaceuticals (ARWR) CEO Christopher Anzalone on Fiscal Q2 2018 Results - Earnings Call TranscriptArrowhead Pharmaceuticals' (ARWR) CEO Christopher Anzalone on Fiscal Q2 2018 Results - Earnings Call Transcript
seekingalpha.com - May 9 at 8:37 AM
Arrowhead Pharmaceuticals (ARWR) Price Target Increased to $11.00 by Analysts at Piper JaffrayArrowhead Pharmaceuticals (ARWR) Price Target Increased to $11.00 by Analysts at Piper Jaffray
www.americanbankingnews.com - May 8 at 9:14 PM
Arrowhead Pharmaceuticals (ARWR) Raised to "Overweight" at Cantor FitzgeraldArrowhead Pharmaceuticals (ARWR) Raised to "Overweight" at Cantor Fitzgerald
www.americanbankingnews.com - May 8 at 9:14 PM
Arrowhead Pharmaceuticals beats by $0.01, misses on revenueArrowhead Pharmaceuticals beats by $0.01, misses on revenue
seekingalpha.com - May 8 at 5:20 PM
Arrowhead Research: Fiscal 2Q Earnings SnapshotArrowhead Research: Fiscal 2Q Earnings Snapshot
finance.yahoo.com - May 8 at 5:20 PM
Arrowhead Pharmaceuticals Reports Fiscal 2018 Second Quarter ResultsArrowhead Pharmaceuticals Reports Fiscal 2018 Second Quarter Results
finance.yahoo.com - May 8 at 5:20 PM
Arrowhead Pharmaceuticals Ready To Break Out Of Its $7 Trading RangeArrowhead Pharmaceuticals Ready To Break Out Of Its $7 Trading Range
seekingalpha.com - May 5 at 5:20 PM
Arrowhead Pharmaceuticals (ARWR) Rating Increased to Strong-Buy at ValuEngineArrowhead Pharmaceuticals (ARWR) Rating Increased to Strong-Buy at ValuEngine
www.americanbankingnews.com - May 2 at 11:35 PM
$4.04 Million in Sales Expected for Arrowhead Pharmaceuticals (ARWR) This Quarter$4.04 Million in Sales Expected for Arrowhead Pharmaceuticals (ARWR) This Quarter
www.americanbankingnews.com - May 2 at 3:56 AM
 Brokerages Expect Arrowhead Pharmaceuticals (ARWR) to Post -$0.18 EPS Brokerages Expect Arrowhead Pharmaceuticals (ARWR) to Post -$0.18 EPS
www.americanbankingnews.com - April 30 at 11:20 AM
Insider Selling: Arrowhead Pharmaceuticals (ARWR) Director Sells 25,000 Shares of StockInsider Selling: Arrowhead Pharmaceuticals (ARWR) Director Sells 25,000 Shares of Stock
www.americanbankingnews.com - April 25 at 10:16 PM
Arrowhead Pharmaceuticals to Webcast Fiscal 2018 Second Quarter ResultsArrowhead Pharmaceuticals to Webcast Fiscal 2018 Second Quarter Results
finance.yahoo.com - April 24 at 5:10 PM
Arrowhead Pharmaceuticals (ARWR) Set to Announce Quarterly Earnings on TuesdayArrowhead Pharmaceuticals (ARWR) Set to Announce Quarterly Earnings on Tuesday
www.americanbankingnews.com - April 24 at 5:17 AM
Arrowhead Pharmaceuticals (ARWR) Stock Rating Lowered by BidaskClubArrowhead Pharmaceuticals (ARWR) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - April 19 at 11:10 AM
Arrowhead Pharmaceuticals (ARWR) Expected to Announce Quarterly Sales of $4.04 MillionArrowhead Pharmaceuticals (ARWR) Expected to Announce Quarterly Sales of $4.04 Million
www.americanbankingnews.com - April 15 at 4:05 AM
Arrowhead Pharmaceuticals: Sneaky Upside Present Over The Course Of 2018Arrowhead Pharmaceuticals: Sneaky Upside Present Over The Course Of 2018
seekingalpha.com - April 13 at 5:19 PM
Arrowhead Pharmaceuticals (ARWR) Expected to Post Earnings of -$0.18 Per ShareArrowhead Pharmaceuticals (ARWR) Expected to Post Earnings of -$0.18 Per Share
www.americanbankingnews.com - April 13 at 11:34 AM
Pre-Open Movers 04/11: (VHC) (LKM) (ARWR) Higher; (BW) (ALOG) (LAYN) Lower (more...)Pre-Open Movers 04/11: (VHC) (LKM) (ARWR) Higher; (BW) (ALOG) (LAYN) Lower (more...)
www.streetinsider.com - April 12 at 9:07 AM
Arrowhead Pharmaceuticals (ARWR) Downgraded to "Buy" at BidaskClubArrowhead Pharmaceuticals (ARWR) Downgraded to "Buy" at BidaskClub
www.americanbankingnews.com - April 10 at 11:29 AM
Arrowhead Pharmaceuticals (ARWR) Lifted to Sell at ValuEngineArrowhead Pharmaceuticals (ARWR) Lifted to Sell at ValuEngine
www.americanbankingnews.com - April 8 at 1:29 PM
Arrowhead Pharmaceuticals Announces Multiple Presentations at The International Liver Congress™Arrowhead Pharmaceuticals Announces Multiple Presentations at The International Liver Congress™
finance.yahoo.com - April 5 at 9:37 AM
Arrowhead Pharmaceuticals (ARWR) Upgraded to Buy at ValuEngineArrowhead Pharmaceuticals (ARWR) Upgraded to Buy at ValuEngine
www.americanbankingnews.com - April 3 at 7:35 PM
Arrowhead Pharmaceuticals Corp (ARWR) Announces Multiple Presentations at The International Liver CongressArrowhead Pharmaceuticals Corp (ARWR) Announces Multiple Presentations at The International Liver Congress
www.streetinsider.com - April 3 at 5:21 PM
Top Stocks Under $10Top Stocks Under $10
www.forbes.com - April 3 at 8:23 AM
Arrowhead Pharmaceuticals Inc (ARWR) Receives Average Recommendation of "Buy" from BrokeragesArrowhead Pharmaceuticals Inc (ARWR) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - April 1 at 5:48 AM

SEC Filings

Arrowhead Pharmaceuticals (NASDAQ:ARWR) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Arrowhead Pharmaceuticals (NASDAQ ARWR) Stock Chart for Saturday, May, 26, 2018

Loading chart…

This page was last updated on 5/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.